Kiniksa Pharmaceuticals CSO Resignation and Transition to Consultant Role

On April 30, 2026, Eben Tessari informed Kiniksa Pharmaceuticals International, plc of his resignation as Chief Strategy Officer to pursue another executive position in the life sciences industry. His departure is effective May 15, 2026, and is not due to any disagreement with the company. Following his resignation, Tessari will transition to a consulting role with the company and serve as an advisor to the Science and Research Committee. The Consulting Agreement, effective May 15, 2026 through May 15, 2027, provides for Tessari to receive compensation of $450 per hour for up to 20 hours per month of services, plus reimbursement for reasonable pre-approved expenses. The agreement can be renewed for an additional year by mutual consent and may be terminated by either party with prior written notice.